SynAct Pharma AB (SYNACT.ST)
SEK 18.2
(4.48%)
SEK 18.2
(4.48%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 224.49 Million SEK | 112.38% |
| 2022 | 105.7 Million SEK | 37.82% |
| 2021 | 76.69 Million SEK | 145.16% |
| 2020 | 31.28 Million SEK | 26.14% |
| 2019 | 24.8 Million SEK | -12.64% |
| 2018 | 28.39 Million SEK | 56.06% |
| 2017 | 18.19 Million SEK | 8.4% |
| 2016 | 16.78 Million SEK | 3440.64% |
| 2015 | 474 Thousand SEK | -5.77% |
| 2014 | 503 Thousand SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 25.65 Million SEK | 55.43% |
| 2024 Q2 | 19.03 Million SEK | -25.83% |
| 2024 Q3 | 24.26 Million SEK | 27.49% |
| 2023 Q2 | 43.49 Million SEK | -25.32% |
| 2023 Q4 | 16.5 Million SEK | -47.91% |
| 2023 Q3 | 31.69 Million SEK | -27.14% |
| 2023 FY | 149.1 Million SEK | 41.05% |
| 2023 Q1 | 58.24 Million SEK | 90.83% |
| 2022 Q2 | 26.41 Million SEK | 18.45% |
| 2022 Q4 | 30.52 Million SEK | 15.35% |
| 2022 FY | 105.7 Million SEK | 37.82% |
| 2022 Q1 | 22.3 Million SEK | -14.72% |
| 2022 Q3 | 26.46 Million SEK | 0.17% |
| 2021 Q4 | 26.15 Million SEK | 25.23% |
| 2021 FY | 76.69 Million SEK | 145.16% |
| 2021 Q3 | 20.88 Million SEK | 33.85% |
| 2021 Q2 | 15.6 Million SEK | 10.99% |
| 2021 Q1 | 14.05 Million SEK | 35.75% |
| 2020 Q3 | 8.98 Million SEK | 51.88% |
| 2020 Q4 | 10.35 Million SEK | 15.26% |
| 2020 FY | 31.28 Million SEK | 26.14% |
| 2020 Q1 | 5.99 Million SEK | -32.31% |
| 2020 Q2 | 5.91 Million SEK | -1.4% |
| 2019 Q2 | 6.48 Million SEK | 26.33% |
| 2019 Q4 | 8.86 Million SEK | 105.86% |
| 2019 FY | 24.8 Million SEK | -12.64% |
| 2019 Q1 | 5.13 Million SEK | -32.07% |
| 2019 Q3 | 4.3 Million SEK | -33.64% |
| 2018 Q3 | 7.4 Million SEK | -25.32% |
| 2018 Q4 | 7.56 Million SEK | 2.06% |
| 2018 FY | 28.39 Million SEK | 56.06% |
| 2018 Q2 | 9.92 Million SEK | 183.34% |
| 2018 Q1 | 3.5 Million SEK | -52.8% |
| 2017 FY | 18.19 Million SEK | 8.4% |
| 2017 Q1 | 3.38 Million SEK | -63.61% |
| 2017 Q4 | 7.41 Million SEK | 243.68% |
| 2017 Q3 | 2.15 Million SEK | -58.72% |
| 2017 Q2 | 5.22 Million SEK | 54.38% |
| 2016 Q2 | 5.56 Million SEK | 0.0% |
| 2016 Q3 | 2.08 Million SEK | -62.6% |
| 2016 Q4 | 9.3 Million SEK | 346.84% |
| 2016 FY | 16.78 Million SEK | 3440.64% |
| 2015 FY | 474 Thousand SEK | -5.77% |
| 2014 FY | 503 Thousand SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 85.174% |
| Camurus AB (publ) | 1.05 Billion SEK | 78.814% |
| Mendus AB (publ) | 129.13 Million SEK | -73.843% |
| Lipum AB (publ) | 37.3 Million SEK | -501.753% |
| NextCell Pharma AB | -576.01 Thousand SEK | 39073.714% |
| Simris Alg AB (publ) | 38.64 Million SEK | -480.964% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -692.534% |
| Active Biotech AB (publ) | 44.8 Million SEK | -401.006% |
| Amniotics AB (publ) | 29.07 Million SEK | -672.207% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -1432.082% |
| BioArctic AB (publ) | 89.62 Million SEK | -150.478% |
| Cantargia AB (publ) | 290.01 Million SEK | 22.592% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -925.33% |
| CombiGene AB (publ) | 44.14 Million SEK | -408.553% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | -57.004% |
| Genovis AB (publ.) | 88.19 Million SEK | -154.539% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -95.09% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -2988.828% |
| Intervacc AB (publ) | 79.78 Million SEK | -181.376% |
| Kancera AB (publ) | 63.07 Million SEK | -255.908% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -3967.693% |
| LIDDS AB (publ) | 27.75 Million SEK | -708.936% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -2994.789% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | -65.177% |
| OncoZenge AB (publ) | 15.9 Million SEK | -1311.481% |
| Saniona AB (publ) | 1.07 Million SEK | -20744.568% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 30.174% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 37.226% |
| Xintela AB (publ) | 57.31 Million SEK | -291.681% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | -23.53% |
| Ziccum AB (publ) | 27.87 Million SEK | -705.28% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -1268.795% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 26.896% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -426.59% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -1169.558% |
| Corline Biomedical AB | 30.16 Million SEK | -644.153% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -286.855% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -169.927% |
| Aptahem AB (publ) | 10.01 Million SEK | -2142.058% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | -66.671% |
| Fluicell AB (publ) | 28.61 Million SEK | -684.485% |
| Biovica International AB (publ) | 133.72 Million SEK | -67.883% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -1034.391% |
| AcouSort AB (publ) | 25.87 Million SEK | -767.584% |
| Abliva AB (publ) | 27.86 Million SEK | -705.627% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | -16.019% |
| 2cureX AB (publ) | 36.51 Million SEK | -514.754% |
| I-Tech AB | 40.14 Million SEK | -459.171% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 73.879% |
| Cyxone AB (publ) | 28.21 Million SEK | -695.69% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -105.267% |
| Biosergen AB | 26.8 Million SEK | -737.39% |
| Nanologica AB (publ) | 69.88 Million SEK | -221.227% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -408.185% |
| BioInvent International AB (publ) | 441.4 Million SEK | 49.14% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -837.186% |
| Alzinova AB (publ) | 36.39 Million SEK | -516.815% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 22.52% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -2757.54% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -102.405% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -1427.184% |